Christoph W.G. Engeler

Christoph’s experience includes advising:

• Novo Nordisk on the acquisition of Cardior Pharmaceuticals
• Cheplapharm:
  • On the acquisition of the worldwide commercial rights (excluding South Korea) for Gemzar® from Eli Lilly and Company 
  • On the sale and acquisition of certain assets (e.g. intellectual property rights and trademarks) of Teva in connection with the pharmaceutical product Myocet liposomal
  • On the acquisition of the US Marketing Authorization for Pulmicort Flexhaler, a Budesonide inhalation powder for the treatment of Asthma, from AstraZeneca AB
  • On the acquisition of the worldwide commercial rights (excluding South Korea) for Zyprexa® from Eli Lilly and Company 
• Inari Medical on the acquisition of LimFlow
• Acrotec Group, a portfolio company of The Carlyle Group, on the acquisition of Friedrich Daniels GmbH, a leading manufacturer of surgical instruments and complete solutions 
• University Heart Center Berlin on the formation of a joint heart center by the Berlin University Hospital Charité and the German Heart Center Berlin
• The Carlyle Group regarding the acquisition and subsequent sale of Alloheim, one of the largest nursing home operators
• Antin Infrastructure Partners on the acquisition of laboratory group amedes
• Malteser Order on first interdenominational hospitals merger in Germany
• Astellas Pharma:
  • On the acquisition of Ganymed Pharmaceuticals and sale of its dermatology business to LEO Pharma
  • On the sale of the worldwide marketing authorizations, trademarks and other assets relating to Mycamine or Fungard to Sandoz AG
• Juno Therapeutics on its cross-border acquisition of Stage Cell Therapeutics GmbH, a privately held biotechnology company
• Treos Bio on regulatory matters in connection with individual healing attempts of personalized medicine in several jurisdictions
• Boston Scientific on the acquisition of StarMedTec, a manufacturer of medical laser Systems
• Siemens in connection with the legal separation of its global healthcare division (diagnostic medical devices) — one of the largest in this industry — involving more than 200 countries as well as the subsequent IPO of Siemens Healthineers